VERAXA's July 6 BiTAC platform update and partnering progress
VERAXA's July 6 BiTAC platform update and partnering progress drive 28% VRXA surge
- July 6 PR details H1 2026 advances: 4 BiTAC-TCE programs for solid tumors, 2 bsADC programs; lead VXA-102 targeting IND/CTA readiness by early 2028
- Company prioritizing BiTAC platform investments; plans to monetize non-core assets (VXA-901 FLT3 mAb, HER2-ADC) to fund core pipeline growth
- Highlights tangible partner interest and positive feedback from BIO 2026 conference amid booming TCE/ADC sector with recent multibillion-dollar deals
- Builds on July 2 cell line development news with ATUM and June 18 in vitro POC for BiTAC-ADC, validating differentiated conditionally active tech
- Post-SPAC listing volatility (June 11 debut; traded as high as ~$27, recently ~$2 range) amplifies move on renewed optimism and sector comps
- No new clinical data or signed deal announced, but strategic clarity, milestones, and partnering momentum sparked buying on July 7
- High trading volume reflects retail and biotech investor interest in next-gen oncology platforms per news wires and market data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.